Subclinical hypothyroidism (SCH) is not associated with metabolic derangement, cognitive impairment, depression or poor quality of life (QoL) in elderly subjects

2010 ◽  
Vol 50 (3) ◽  
pp. e68-e73 ◽  
Author(s):  
Young Joo Park ◽  
Eun Jung Lee ◽  
You Jin Lee ◽  
Sung Hee Choi ◽  
Joon Hyuk Park ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Cognitive Impairment ◽  
Subclinical Hypothyroidism ◽  
Poor Quality ◽  
Elderly Subjects ◽  
Metabolic Derangement

scholarly journals Anxiety: a hidden element in dementia

2012 ◽  
Vol 18 (2) ◽  
pp. 119-128 ◽  
Author(s):  
Vellingiri Raja Badrakalimuthu ◽  
Andrew F. Tarbuck
Keyword(s):  
Quality Of Life ◽  
Cognitive Impairment ◽  
Anxiety Disorders ◽  
Old Age ◽  
Negative Impact ◽  
Poor Quality ◽  
Therapeutic Options ◽  
Prevalence Rates ◽  
People With Dementia

SummaryAnxiety has reported prevalence rates between 38 and 72% among people with dementia. It has a negative impact on cognitive impairment and is associated with agitation and poor quality of life. The presence of excessive anxiety can be difficult to establish in people with dementia, especially when expressive or receptive speech is impaired. Unfortunately, there is a lack of research on the treatment of anxiety in dementia, and also on the wider issue of the management of anxiety disorders in old age. We explore the prevalence, presentation and diagnosis of anxiety in dementia and discuss the therapeutic options available.

scholarly journals To Treat or Not to Treat Subclinical Hypothyroidism, What Is the Evidence?

Medicina ◽  
2020 ◽  
Vol 56 (1) ◽  
pp. 40
Author(s):  
Jan Calissendorff ◽  
Henrik Falhammar
Keyword(s):  
Quality Of Life ◽  
Cardiovascular Risk ◽  
Subclinical Hypothyroidism ◽  
Thyroid Stimulating Hormone ◽  
Term Treatment ◽  
Elderly Subjects ◽  
Subclinical Disease ◽  
Wait And See ◽  
Levothyroxine Treatment

Objective: levothyroxine prescriptions have increased remarkably during the last decade, and it is most likely to be prescribed in subclinical hypothyroidism. The aim of this review was to present data on when levothyroxine treatment should be initiated, and the effects of treatment in subclinical hypothyroidism on symptoms such as weight, quality of life, vitality, cognition, and cardiovascular disease. We also discuss evidence for different thyroid-hormone medications. In addition, the option to withhold medication when there is uncertain diagnosis or lack of clinical improvement is discussed. Methods: a literature search in PubMed on the term “treatment of subclinical hypothyroidism” in combination with “quality of life”, “weight”, “cognition”, and “cerebrovascular disease”. Results: current research supports that levothyroxine should be initiated in patients with a thyroid stimulating hormone (TSH) >10 mIU/L. Treatment for hypothyroidism is becoming more frequent. Symptoms related to vitality, weight, and quality of life in subclinical disease often persist with levothyroxine treatment, and other causes should be explored. Patients with cardiovascular-risk factors may benefit from treatment, especially younger patients. Caution is necessary when treating elderly subjects with levothyroxine. Conclusion: lifelong treatment with levothyroxine should normally only be considered in manifest hypothyroidism. However, in subclinical hypothyroidism with a TSH >10 mIU/L, therapy is indicated. In milder subclinical forms, a wait-and-see strategy is advocated to see if normalization occurs. Subgroups with cardiovascular risk and subclinical hypothyroidism may benefit from levothyroxine therapy.

scholarly journals AB0551 CLINICAL SIGNIFICANCE OF COGNITIVE IMPAIRMENT AND MALNUTRITION IN PATIENTS WITH SYSTEMIC SCLEROSIS

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1572.2-1572
Author(s):  
D. Benfaremo ◽  
L. Manfredi ◽  
I. Paterno ◽  
C. Dichiara ◽  
A. M. Risa ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Cognitive Impairment ◽  
Systemic Sclerosis ◽  
Cognitive Dysfunction ◽  
Poor Quality ◽  
Regression Analyses ◽  
Chi Square ◽  
Sf 36 ◽  
Chi Square Test

Background:Previous studies reported a high prevalence of cognitive dysfunction in systemic sclerosis (SSc). Cognitive impairment was estimated to involve 60% to 80% of SSC patients and to be correlated with older age, disease severity, diffuse cutaneous subset and poor quality of life.Objectives:The aim of our study was to evaluate the association between cognitive impairment, nutritional status and the quality of life of SSc patients.Methods:Sixty-eight consecutive SSc patients followed at our Institution were evaluated for cognitive impairment using the validated Italian version of the Montreal Cognitive Assessment (MoCA). Scores <26 were considered abnormal. We also assessed other domains and quality of life measures such as UCLA SCTC GIT 2.0 for gastrointestinal involvement, BDI-II and PHQ-9 for anxiety and depression, EAT-10 for dysphagia symptoms, SHAQ and SF-36 for function and quality of life (QoL). The risk and the presence of overt malnutrition were assessed using the MUST questionnaire and the GLIM criteria, respectively. Clinical and demographic parameters such as age, sex, BMI, disease subset, organ involvement, autoantibody profile and modified Rodnan Skin Score were also recorded for each patient. Data were analysed by Student t-test or chi-square test and regression analyses were used to assess the association between variables.Results:A total of 68 SSc patients [47 (69.1%) limited SSc (lSSc) and 21 (30.9%) with diffuse SSc (dSSc), 59 female; mean age 60.2 (±13.4) years; mean disease duration 9 (±8.2) years; mean mRSS 8.1 (±7.6)] were included in the study.Cognitive impairment was identified in 30 (44.1%) SSc patients; the mean MoCA score was 24.7 (±4.3). According to GLIM criteria, 16 (23.5%) patients were malnourished. Compared to patients with a MoCA≥26, patients with cognitive impairment were older (p<0.001), had more comorbidities (p<0.0001) and a worse QoL as assessed by the physical and general health domains of the Sf-36 (p<0.05). Malnourished patients were significantly more dysphagic (p<0.01) and had a worse HAQ (p<0.01) compared to well-fed patients. On regression analyses, cognitive impairment was related to increasing age (OR 1.08, 95%CI 1.03 to 1.14, p=0.001), but not to malnutrition, disease subset or symptoms. Malnutrition was associated with dysphagia (OR 1.10, 95%CI 1.01 to 1.20, p=0.01) and HAQ score (OR 2.69, 95%CI 1.24 to 5.82, p=0.01), but was not predicted by cognitive impairment.Conclusion:Cognitive dysfunction is frequently observed in SSc patients and mostly associated with increasing age and number of comorbidities. Malnutrition and cognitive impairment are both associated to QoL but seem to be unrelated.Disclosure of Interests:None declared

scholarly journals Poststroke depression and its impact on quality of life

Medicina ◽  
2007 ◽  
Vol 43 (1) ◽  
pp. 1 ◽  
Author(s):  
Daiva Rastenytė ◽  
Daina Krančiukaitė
Keyword(s):  
Quality Of Life ◽  
Risk Factor ◽  
Cognitive Impairment ◽  
Mortality Rates ◽  
Poor Quality ◽  
Psychosocial Outcome ◽  
Poststroke Depression ◽  
Stroke Patients ◽  
Common Problems

Depression is one of the most common problems after stroke. Depression is not only frequently occurring outcome of stroke, but stroke is also a clear risk factor for depression. Depression after stroke can affect anyone regardless of his/her age, sex, background, or the severity of stroke. It can develop immediately after the stroke or weeks or months later. Many people are not routinely assessed for depression after stroke, and only a minority are properly diagnosed and treated. Patients with poststroke depression have lower functional status, increased cognitive impairment, and higher mortality rates than stroke patients without depression. Poststroke depression is also associated with poor psychosocial outcome and poor quality of life; therefore, there is a strong case for the early diagnosis and treatment of poststroke depression.

scholarly journals Thyroid status and functional and cognitive status at baseline and survival after 3 years of follow-up: the OCTABAIX study

2014 ◽  
Vol 170 (1) ◽  
pp. 69-75 ◽  
Author(s):  
Francesc Formiga ◽  
Assumpta Ferrer ◽  
Gloria Padros ◽  
Anna Contra ◽  
Xavier Corbella ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Cognitive Function ◽  
Subclinical Hypothyroidism ◽  
Oldest Old ◽  
Cognitive Status ◽  
Elderly Subjects ◽  
Thyroid Disorders ◽  
Thyroid Status

ObjectiveSubclinical thyroid disorders are common in older individuals. Health risks associated with subclinical hypothyroidism in older adults are unclear. The aim of the study is to evaluate whether thyroid status in elderly subjects correlates with physical and cognitive function at baseline and with 3-year mortality.DesignA population-based, prospective cohort of the OCTABAIX study (307 inhabitants aged 85 years at baseline).MethodsChronic drug prescription, functional status (Barthel and Lawton indices) and cognitive status according to the Spanish version of the Mini-Mental State Examination were recorded. Quality of life was assessed using the visual analogue scale of the quality of life test. Concentrations of TSH and thyroxine were measured. Participants were classified in accordance with clinical categories of thyroid function.ResultsTwenty (6.5%) individuals had subclinical hypothyroidism and five (1.6%) had subclinical hyperthyroidism. Compared with euthyroid subjects (n=280; 91.8%), subclinical hypo- and hyperthyroidism subjects were not significantly associated with poor physical or cognitive function at baseline. Fifty-one (15.1%) subjects died during the 36 months of follow-up. TSH values and subclinical hypo- and hyperthyroidism were not associated with an increased overall mortality risk (hazard ratio (HR) 1.086, 95% CI 0.987–1.196 and HR 0.905, 95% CI 0.902–1.053 respectively).ConclusionsThis study does not support the association of TSH or thyroid disorders with physical or cognitive function at baseline or with 3-year mortality in the oldest old subjects.

KUALITAS HIDUP PASIEN STROKE DI POLIKLINIK RAWAT JALAN RUMAH SAKIT SWASTA YOGYAKARTA

2019 ◽  
Vol 7 (3) ◽  
pp. 232-237
Author(s):  
Hana Larasati ◽  
Theresia Titin Marlina
Keyword(s):  
Quality Of Life ◽  
Social Relations ◽  
Hemorrhagic Stroke ◽  
Poor Quality ◽  
Social Dimension ◽  
Stroke Patients ◽  
Sampling System ◽  
Post Stroke ◽  
Psychological Dimension

Background: stroke is a disorder of nervous system function that occurs suddenly and is caused by brain bleeding disorders that can affect the quality of life physical dimensions, social dimensions, psychological dimensions, environmental dimensions. Based on the result of Lumbu study (2015) the number of samples were 71 people collected data using the (WHOQOL-BREF). There were 56 people (78,9%) had the poor quality of life of post stroke. The mean of post-stroke quality of life domain was physical domain (45,27%), psychological domain (49,87%), social relations domain (48,15%) and environmental domain (50.01%). Objective: the purpose of the study was know the quality of life of the stroke patients in Outpatient Polyclinic of Private Hospital in Yogyakarta. Methods: used descriptive quantitative by using questionnaire test of purposive sampling system based on patients who have been affected of ischemic or hemorrhagic stroke before, number 30 respondents. Result: quality of life of stroke patient of medium physical dimension (67%), psychological dimension (71%), social dimension (67%), dimension good environment (63%). Conclusion: the quality of life of stroke patients of physical dimension, psychological dimension, and moderate social dimension, while the quality of life of stroke patients were good environmental dimension.   Keywords: Hemorrhagic stroke, ischemic stroke, quality of life

scholarly journals Evaluation of the efficacy of hearing aids in older adults: a multiparametric longitudinal study protocol

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Domenico Cuda ◽  
Sara Ghiselli ◽  
Alessandra Murri
Keyword(s):  
Quality Of Life ◽  
Older Adults ◽  
Speech Perception ◽  
Hearing Aids ◽  
Assessment Tools ◽  
Elderly Subjects ◽  
Single Subject ◽  
Measurement Tools ◽  
First Time

Abstract Background Prevalence of hearing loss increases with age. Its estimated prevalence is 40–50 % in people over 75 years of age. Recent studies agree that declinein hearing threshold contribute to deterioration in sociality, sensitivity, cognition, and quality of life for elderly subjects. The aim of the study presented in this paper is to verify whether or not rehabilitation using first time applied Hearing Aids (HA) in a cohort of old people with hearing impairment improves both speech perception in a noisy environment over time and the overall health-related quality of life. Methods The monocentric, prospective, repeated measurements, single-subject, clinical observational study is to recruit 100 older adults, first-time HA recipients (≥ 65 years).The evaluation protocol is designed to analyze changes in specific measurement tools a year after the first HA usage in comparison with the evaluation before HA fitting. Evaluations will consist of multiparametric details collected through self-report questionnaires completed by the recipients and a series of commonly used audiometric measures and geriatric assessment tools. The primary indicator of changes in speech perception in noise to be used is the Italian version of Oldenburg Satz (OLSA) test whereas the indicator of changes in overall quality of life will be the Assessment of Quality of Life (AQoL) and Hearing Handicap Inventory for the Elderly (HHIE) questionnaires. The Montreal Cognitive Assessment (MoCA) will help in screening the cognitive state of the subjects. Discussion The protocol is designed to make use of measurement tools that have already been applied to the hearing-impaired population in order to compare the effects of HA rehabilitation in the older adults immediately before first HA usage (Pre) and after 1 year of experience (Post). This broad approach will lead to a greater understanding of how useful hearing influences the quality of life in older individuals, and therefore improves potentials for healthy aging. The data is to be analyzed by using an intrasubject endpoint comparison. Outcomes will be described and analyzed in detail. Trial registration This research was retrospectively registered underno. NCT04333043at ClinicalTrials.gov (http://www.clinicaltrials.gov/) on the 26 March 2020. This research has been registered with the Ethics Committee of the Area Vasta Emilia Nord under number 104, date of approval 17/07/2017.

Sign in / Sign up

Export Citation Format

Share Document